Patients whose underlying medical conditions might be compromised by increases in BP, hypokalemia or fluid retention eg, those w/ heart failure, recent MI or ventricular arrhythmia. History of CV disease. HTN & hypokalemia must be controlled prior to therapy. Monitor BP, serum K & fluid retention at least mthly. Monitor for adrenocortical insufficiency; symptoms of mineralocorticoid excess. Discontinue if patient develops severe hepatotoxicity. Hepatic impairment. Not for use in women.